NCT00183950终止1 期
Phase I/II Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 2
研究概览
简要总结
This study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which has failed to shrink or has returned after previous treatment with chemotherapy. The purpose of this study is to find out whether patients with these types of cancer will have their tumor shrunk after treatment with a drug called Noscapine. The second purpose is to see what are the side effects of this drug. This drug is being used as an over-the-counter cough suppressor in Europe and Japan, but has also shown to be effective against cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with low grade NHL (follicular lymphoma, small cell lymphocytic lymphoma, marginal cell lymphoma, monocytoid B-cell lymphoma, MALT lymphoma, plasmacytoid lymphocytic lymphoma) or chronic lymphocytic leukemia who have demonstrated chemotherapy resistance (have not achieved CR,CRu, PR)or who have relapsed at any time following a response (CR, CRu, PR) after at least one therapy regimen, including chemotherapy, Rituximab, or high dose chemotherapy with stem cell rescue.
- •Karnofsky performance status 60 % or greater.
- •Creatinine less or equal to 2.0 mg/dl, bilirubin less or equal to 2.0 mg/dl, SGPT/SGOT less or equal to 4 x upper normal range
排除标准
- •Patients with unconfirmed complete response(CRu)after last treatment and who currently remain in CRu.
- •Pregnant or lactating women.
- •Disease-specific treatment less than 1 month prior to starting this study.
- •CNS disease.
- •HIV-positive patients.
- •Other cancer, except basal cell or squamous cell cancer of the skin or carcinoma in-situ of cervix.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)NonHodgkin LymphomaLymphoproliferative DisordersEBV Related LymphomaEBV-Related PTLDEBV Related Non-Hodgkin's LymphomaEBV Related Hodgkin's LymphomaHodgkin LymphomaNCT02973113Baylor College of Medicine8
已完成
2 期
Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's LymphomaLow-Grade LymphomaNCT00003499Burzynski Research Institute31
已完成
2 期
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic ChemotherapyChemotherapy-Induced Nausea and VomitingNon Hodgkin's LymphomaNCT01018758Gruppo Italiano Studio Linfomi86
撤回
1 期
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)Non-Hodgkin's B-cell LymphomaNCT04148742Dizal Pharmaceuticals120
已完成
2 期
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaRelapsed LymphomaRefractory LymphomaLow-Grade LymphomaIntermediate-Grade LymphomaNCT00054808Genta Incorporated40